Caladrius Biosciences, Inc. (NASDAQ:CLBS) stem cell therapist, is reporting third quarter earnings results on Thursday 5th November 2020, after market close.
The consensus estimates from Thomson Reuters are loss of $ 0.29 per share.
For the full year, analysts predict loss of $ 1.07 per share.
Stock Performance
Shares of Caladrius Biosciences, Inc. traded up $ 0.01 or 0.63 percent on Wednesday, reaching $ 1.59 with volume of 73.30 thousand shares. Caladrius Biosciences, Inc. has traded high as $ 1.61 and has cracked $ 1.53 on the downward trend
The closing price of $ 1.59, representing a 50.48 % increase from the 52 week low of $ 1.05 and a 56.59 % decrease over the 52 week high of $ 3.64.
The company has a market capital of $ 30.72 million and is part of the Healthcare sector and Specialized Health Services industry.
